Crossmark

Quality of life under treatment with the immune checkpoint inhibitors ipilimumab and nivolumab in melanoma patients. Real-world data from a prospective observational study at the Skin Cancer Center Kiel

Crossref DOI link: https://doi.org/10.1007/s00432-024-05981-2

Published Online: 2024-10-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Grote, Carolin

Bohne, Ann-Sophie

Blome, Christine

Kähler, Katharina C.
Funding

Funding for this research was provided by:

Universitätsklinikum Schleswig-Holstein - Campus Kiel
License Information

Text and Data Mining valid from 2024-10-10

Version of Record valid from 2024-10-10
More Information

Article History

Received: 30 July 2024

Accepted: 30 September 2024

First Online: 10 October 2024

Declarations

:

: Carolin Grote received travel grants from Almirall and Celltrion and speaker fees from BMS and MSD; Ann-Sophie Bohne has received travel grants from Sun Pharma, Pierre-Fabre, BMS and Mallinckrodt Pharmaceuticals; Christine Blome has received speaker honoraria, research grants and/or awards from Amgen/Celgene, AstraZeneca, Bauerfeind, Deutsche Gesellschaft für ME/CFS, Hartmann, Helios Klinik Leisnig, Janssen-Cilag, Kreussler, Lilly, Mapi Group, medi, Pfizer, Stiefel Laboratories, The EuroQol Group, UCB, and Urgo; Katharina Kähler serves as consultant to Philogen, BMS, MSD, Sanofi Aventis, Immunocore and received travel grants and speaker fees from Philogen, Pierre Fabre, BMS, MSD, Sun Pharma, Sanofi Aventis, Novartis, Medac and has received research support by Novartis.

Document is current

Any future updates will be listed below